Pabban Development, Inc. v. Kyphon Sarl , 673 F. App'x 612 ( 2016 )


Menu:
  •                                                                             FILED
    DEC 08 2016
    MOLLY C. DWYER, CLERK
    U.S. COURT OF APPEALS
    NOT FOR PUBLICATION
    UNITED STATES COURT OF APPEALS
    FOR THE NINTH CIRCUIT
    PABBAN DEVELOPMENT, INC.,
    Plaintiff - Appellee,            No. 14-56465, 14-56696
    v.                                           D.C. No. 8:10-cv-533-BRO-RNB
    KYPHON SARL AND MEDTRONIC,
    INC.,
    ORDER
    Defendants - Appellants.
    1
    Before: BYBEE and TASHIMA, Circuit Judges, and ZIPPS,* District Judge.
    The Memorandum Disposition filed November 16, 2016 and appearing at
    
    2016 WL 6777337
     (9th Cir. 2016) is hereby WITHDRAWN. The attached
    Memorandum Disposition replacing the previous Memorandum Disposition shall
    be filed simultaneously with this order.
    1
    *The Honorable Jennifer G. Zipps, United States District Judge for the District
    of Arizona, sitting by designation.
    FILED
    NOT FOR PUBLICATION
    DEC 08 2016
    UNITED STATES COURT OF APPEALS                       MOLLY C. DWYER, CLERK
    U.S. COURT OF APPEALS
    FOR THE NINTH CIRCUIT
    PABBAN DEVELOPMENT, INC.; BIO                    No.   14-56465, 14-56696
    MEDICAL, INC.; BIO MEDICAL
    DEVICES INTERNATIONAL, INC.;                     D.C. No.
    HARRY N. HERBERT;                                8:10-cv-00533-BRO-RNB
    Plaintiffs-counter-
    defendants-Appellees,              MEMORANDUM*
    v.
    KYPHON SARL,
    Defendant-counter-claimant-
    Appellant.
    Appeal from the United States District Court
    for the Central District of California
    Beverly Reid O’Connell, District Judge, Presiding
    Argued and Submitted August 31, 2016
    Pasadena, California
    Before: TASHIMA and BYBEE, Circuit Judges, and ZIPPS,** District Judge.
    *
    This disposition is not appropriate for publication and is not precedent
    except as provided by Ninth Circuit Rule 36-3.
    **
    The Honorable Jennifer G. Zipps, United States District Judge for the
    District of Arizona, sitting by designation.
    Appellant Kyphon Sarl (“Kyphon”) appeals a jury verdict in favor of Pabban
    Development, Inc. (Pabban). The action arises from a dispute between the parties
    regarding Kyphon’s purchase of a medical device, the Natrix System, from
    Pabban. Kyphon claimed the Natrix System was defective and refused to continue
    its payments to Pabban. Pabban filed an action against Kyphon in Orange County
    Superior Court in March 2010; the action was removed to federal district court
    pursuant to 
    28 U.S.C. §§ 1331
     and 1441. The parties alleged cross-claims for
    breach of contract / breach of warranty. The jury found that Kyphon breached its
    purchase contract with Pabban, but that Pabban did not breach its warranty of
    merchantability to Kyphon. Kyphon argues on appeal that the district court
    erroneously denied Kyphon’s motions for judgment as a matter of law, erroneously
    denied Kyphon’s motion for new trial, improperly instructed the jury regarding the
    warranty provisions of the contract, and improperly awarded attorney’s fees to
    Pabban. We affirm.
    The district court’s interpretation of the term “knowledge” in Section 3.16 of
    the parties’ Asset Purchase Agreement (APA) was not legally erroneous such that
    Kyphon is entitled to judgment as a matter of law or a new trial. The district court
    interpreted the APA’s warranty of merchantability to apply if none of Pabban’s
    key personnel were in possession of any knowledge that the Natrix System was not
    2
    of good enough quality to be sold. The district court’s jury instruction on the issue
    of knowledge relied on its February 14, 2014 interpretation of the APA. In its
    August 8, 2014 Order denying Kyphon’s renewed motion for judgment as a matter
    of law and motion for new trial, the district court relied on its February 14, 2014
    minute entry and jury instruction, in concluding that there was sufficient evidence
    to support the jury’s verdict.
    The district court’s interpretations of the APA in the February 14, 2014
    minute entry, the jury instruction and the August 8, 2014 Order were consistent
    with each other and were not contrary to Delaware law. Kyphon’s argument that,
    under Delaware law, the warranty is only satisfied when all three key personnel
    possess affirmative knowledge that the product is of good enough quality to be
    sold, is not supported by applicable law and is contrary to the holdings in Price
    Automotive Group v. Dannemann, 
    2002 WL 31260007
    , *7 (Del. Super. Ct. Sept.
    25, 2002) and Cent. Mortgage Co. v. Morgan Stanley Mortgage Capital Holdings
    LLC, 
    2012 WL 3201139
    , at *9 n.69 (Del. Ch. Aug. 7, 2012). The district court’s
    interpretation of the “knowledge” term does not render contractual warranties
    worthless by permitting warrantors to purposefully remain uninformed about
    defects in the product. The law provides a protection against that outcome in the
    form of a party’s ability to request a jury instruction on this “ostrich approach” if
    3
    evidence suggests that the seller deliberately avoided knowledge that the product
    was not merchantable. See DCV Holdings, Inc. v. Conagra, Inc., 
    2005 WL 698133
    , at *10–12 (Del. Super. Mar. 24, 2005), aff’d, 
    889 A.2d 954
     (Del. 2005).
    For these reasons, the district court’s jury instruction did not unfairly place the
    burden on Kyphon to affirmatively prove that Herbert, Green, and Stark
    affirmatively knew that the Natrix System was not of good enough quality to be
    sold. Because there was no legal error in the district court’s interpretation of the
    term “knowledge” in Section 3.16 of the APA, Kyphon is not entitled to reversal of
    the district court’s denial of Kyphon’s first motion for judgment as a matter of law
    or the district court’s denial of Kyphon’s renewed motion for judgment as a matter
    of law, alternatively motion for a new trial, on this ground.
    Kyphon is not entitled to judgment as a matter of law or a new trial based on
    its claim that insufficient evidence supported the jury’s verdict. Kyphon contends
    that, even if the district court correctly interpreted Section 3.16’s warranty of
    merchantability to apply if none of Pabban’s key personnel were in possession of
    any knowledge that the Natrix System was not of good enough quality to be sold,
    the evidence at trial was insufficient to demonstrate that Pabban complied with its
    warranty obligations. As a threshold matter, this claim by Kyphon presents a
    separate challenge to the district court’s interpretation of the warranty of
    4
    merchantability in its August 8, 2014 Order. According to Kyphon, the term “of
    merchantable quality,” which the district court defined in its February 14, 2014
    minute entry to mean “of good enough quality to be sold,” should be further
    interpreted to mean “of good enough quality to be sold commercially to Kyphon’s
    customers, ie. physicians.”
    The district court was not confronted with the issue of who the Natrix
    System was being sold to within the meaning of the APA until Kyphon filed its
    renewed motion for judgment as a matter of law, and alternatively motion for a
    new trial. The district court properly concluded that there is a difference between
    the quality of a product and its “commerciability” and that in Section 3.16, Pabban
    was warrantying that the Natrix System was of good enough quality to be sold by
    Pabban to Kyphon, not that the Natrix System was of good enough quality to be
    sold on the open market. This interpretation is logical in light of the
    uncontroverted evidence regarding the Natrix System’s developmental stage at the
    time the APA was signed. It appears undisputed that both parties knew at closing
    that the Natrix System could not be sold commercially to physicians until all
    validations, including packaging validations, were obtained. Because both parties
    also knew at closing that Kyphon did not yet have packaging validation for the
    5
    Natrix System, Pabban would have been in immediate breach of the warranty
    under Kyphon’s proposed interpretation, regardless of any leaks in the saline bags.
    Court will only reverse the district court’s decisions if it finds that the
    evidence, construed in the light most favorable to the nonmoving party, permits
    only one reasonable conclusion, and that conclusion is contrary to the jury’s
    verdict. Because the district court properly interpreted “of good enough quality to
    be sold” to mean “of good enough quality to be sold by Pabban to Kyphon,”
    Kyphon is without any argument that the evidence compelled a different verdict.
    When the evidence is viewed in the light most favorable to Pabban, the jury was
    presented with sufficient evidence from which it could conclude that Pabban’s key
    personnel had no actual knowledge that the saline bags were leaking due to an
    inherent defect in the Natrix System – as opposed to a packaging issue – such that
    the Natrix System was not fit for sale by Pabban to Kyphon. Similarly, Kyphon
    has failed to demonstrate that the district court’s denial of Kyphon’s alternative
    motion for a new trial was an abuse of discretion. The jury’s verdict was not
    against the clear weight of the evidence such that the district court should have
    granted a new trial. See Passantino v. Johnson & Johnson Consumer Prods., 
    212 F.3d 493
    , 510 n.15 (9th Cir.
    6
    Finally, the district court did not err in granting Pabban’s post-trial motion
    for attorney’s fees. Pabban was not required to submit evidence of its fees to the
    jury pursuant to Rule 54(d). Fed. R. Civ. P. Rule 54(d)(2) provides: “A claim for
    attorney’s fees and related nontaxable expenses must be made by motion unless the
    substantive law requires those fees to be proved at trial as an element of damages.”
    Kyphon did not demonstrate that Delaware law – the substantive law governing the
    parties’ contract – requires attorney’s fees awarded pursuant to a fee-shifting
    provision of a contract to be proven at trial as an element of damages. Although
    Delaware courts have not directly addressed this issue, case law suggests that
    attorney’s fees awarded pursuant to a fee-shifting provision of a contract may be
    proven in a post-trial motion for fees, separate and apart from damages proven at
    trial. See, e.g., Vigortone Ag Prod., Inc. v. PM Ag Prod., Inc., 
    2004 WL 1899882
    (N.D. Ill. Aug. 12, 2004) (applying Delaware law to a post-trial motion for
    attorneys’ fees pursuant to Rule 54(d), Fed. R. Civ. P.); 2009 Caiola Family Trust
    v. PWA, LLC, 
    2015 WL 6007596
    , at *34 (Del. Ch. Oct. 14, 2015) (directing
    prevailing party to file post-trial documentation of fees following bench trial);
    SIGA Techs., Inc. v. PharmAthene, Inc., 
    67 A.3d 330
    , 353 (Del. 2013) (citing
    Mahani v. Edix Media Grp., Inc., 
    935 A.2d 242
     (Del. 2007) for the proposition that
    “Delaware law dictates that, in fee shifting cases, a judge determine whether the
    7
    fees requested are reasonable.”). In light of Kyphon’s failure to support its
    argument with applicable law, and given the case law which contradicts Kyphon’s
    argument, we cannot conclude that the district court’s award of attorney’s fees in
    this case was based on legal error.
    We do not consider Kyphon’s argument, raised for the first time on appeal,
    that the indemnification provision of the APA did not permit an award of fees. See
    Int’l Union of Bricklayers & Allied Craftsman Local Union No. 20, AFL-CIO v.
    Martin Jaska, Inc., 
    752 F.2d 1401
    , 1404 (9th Cir. 1985) (appellate court will not
    review an issue not raised in the district court unless necessary to prevent manifest
    injustice).
    AFFIRMED
    8